Curious about today's AI digest?ai-tldr.dev

Daily Digest

J&J in Talks to Buy Ollin Biosciences for $3.4B

HealthcareNOTABLE28m ago5 min read
Share
J&J in Talks to Buy Ollin Biosciences for $3.4B

Johnson & Johnson (JNJ) is in advanced talks to acquire Ollin Biosciences for up to $3.4 billion, a deal that would add a late-stage retinal drug to its pipeline.

  • J&J is negotiating a deal worth up to $3.4 billion, including about $2.2 billion upfront.
  • Roughly $1.2 billion would depend on clinical milestones for Ollin's lead drug, OLN324.
  • No agreement has been signed, and the talks could still fall apart.

Lead

Johnson & Johnson is in advanced talks to buy Texas-based eye-disease biotech Ollin Biosciences in a transaction valued at up to $3.4 billion. The structure includes about $2.2 billion in cash upfront and up to $1.2 billion in milestone payments tied to clinical progress. An announcement could come as early as Monday, though terms remain under negotiation and the discussions could still collapse.

What Is J&J Reportedly Paying For Ollin?

J&J would pay about $2.2 billion upfront, with the remaining $1.2 billion payable only if OLN324 reaches defined development targets. Milestone-heavy structures like this let a buyer limit its exposure to trial risk, while giving the seller's investors a path to the headline value.

Ollin's lead asset, OLN324, is a bispecific antibody that targets both VEGF and Ang2, two signals that drive abnormal blood vessel growth and leakage in the retina. The company is developing it for diabetic macular edema and wet age-related macular degeneration. In June, Ollin raised $330 million in a Series B round co-led by TCGX and ARCH Venture Partners to fund global Phase III trials, which are due to start in the second half of 2026. The company launched in 2025 with a $100 million Series A.

Ollin also has OLN102, a bispecific antibody for thyroid eye disease and Graves' disease, which is slated to enter clinical development this year.

Why Is J&J Targeting Retinal Disease?

J&J is targeting retinal disease because it is a large, growing market where the company has little presence in prescription retina therapies. Wet AMD and diabetic macular edema are chronic conditions that require repeated injections, so the drugs that treat them generate recurring revenue.

The market is led by Roche with Vabysmo, a dual-pathway antibody that has taken share from older anti-VEGF injections such as Regeneron's (REGN) Eylea. OLN324 is positioned as a challenger to Vabysmo, which makes it one of the more visible late-stage assets in the category.

Strategic Context

The approach fits a broader pattern of large drugmakers buying clinical-stage biotechs to replenish pipelines as patent expirations near on older blockbusters. A bid for a company about to enter Phase III also follows a familiar pattern, with the buyer paying for validated early data while keeping a large share of the price contingent on later results. J&J has built much of its recent pharmaceutical growth in oncology and immunology, and a retina franchise would widen its therapeutic footprint.

For investors tracking sector deal flow, including those who hold a biotech ETF or a broader healthcare ETF, a signed transaction would add to the year's tally of mid-sized biotech acquisitions. Ollin is privately held, so there is no public share price to react to the talks. JNJ shares are the only listed security directly affected.

Could the Talks Still Collapse?

The talks could still collapse, because no definitive agreement has been signed and terms can change until one is. Disagreement over the upfront payment, the size or triggers of the milestones, or the outcome of due diligence could all derail or reprice the deal. A transaction of this size would also need to clear antitrust review, though J&J's limited retina overlap makes a lengthy challenge less likely.

Outlook

A signed deal would give J&J a Phase III-ready challenger in a market currently led by Roche and Regeneron, at an upfront cost of about $2.2 billion. The next signals are an announcement, the final split between cash and milestones, and the start of OLN324's pivotal trials. If talks fail, Ollin retains its recent $330 million in funding and can proceed independently, or it could attract other bidders.

Mentioned tickers: JNJ, REGN, RHHBY

The Daily Briefing

Every story that moved the market, every weekday.

Market news - the major stories only, free, and one email a day.

One email a day. Unsubscribe anytime.